Please use this identifier to cite or link to this item:
|Title:||Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial.||Austin Authors:||Field, K M;Barnes, E H;Sim, H W;Nowak, A K;Simes, J;Rosenthal, M A;Wheeler, H;Hovey, E J;Cher, Lawrence M||Affiliation:||Neurology
Department of Medical Oncology, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia
Department of Medical Oncology, Prince of Wales Hospital, Barker Street, Randwick, NSW 2031, Australia
Department of Medical Oncology, Royal Melbourne Hospital, Grattan St, Parkville, Vic 3050, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Grattan St, Parkville, Vic 3000, Australia. Electronic address: email@example.com..
Department of Medical Oncology, Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia
School of Medicine and Pharmacology, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia
Department of Medical Oncology, Peter MacCallum Cancer Centre, Grattan St, Parkville, Vic 3000, Australia
National Health and Medical Research Council Clinical Trials Centre, University of Sydney, NSW 2006, Australia
|Issue Date:||12-Nov-2021||metadata.dc.date:||2021-12||Publication information:||Journal of Clinical Neuroscience 2021; 94: 321-327||Abstract:||Assessment of neurocognitive function (NCF) is important in brain tumor clinical trials, however there are varying methodologies available. We used the Cogstate computerized NCF testing battery and the mini-mental state examination (MMSE) to prospectively assess cognition in adult patients with recurrent glioblastoma (GBM) enrolled in the CABARET randomized phase II clinical trial of bevacizumab versus bevacizumab plus carboplatin chemotherapy. We determined completion rates; compared NCF results between trial arms; and assessed baseline NCF as a predictor of survival outcome. 93 of 103 eligible patients completed baseline Cogstate NCF testing. Completion rates were between 60 and 100% across each timepoint, and 38% at disease progression. There was no evidence of difference between arms in time to deterioration in NCF using either test. Prior to disease progression, deterioration on the Cogstate tests was substantially more common (90%) than deterioration on the MMSE (37%), and decline in the Cogstate composite score within the first 8 weeks was associated with shorter overall survival. This testing methodology may be useful when determining net clinical benefit for therapies in patients with recurrent GBM.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/28352||DOI:||10.1016/j.jocn.2021.10.022||Journal:||Journal of Clinical Neuroscience||PubMed URL:||34863458||Type:||Journal Article||Subjects:||Cogstate
Mini-mental state examination
|Appears in Collections:||Journal articles|
Show full item record
checked on Jun 9, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.